MedTrace Logo

Biomarker and Imaging Package Study in Immune Effector Cell-Associated Neurotoxicity Syndrome

NCT05643092 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2023-03-07

No results posted yet for this study

Summary

CAR T-cell therapy is a promising innovative therapy for hematological malignancies. Immune effectors cells-associated neurotoxicity syndrome (ICANS) is a significant complication of CAR therapy. The goal of this study is to understand what brain mechanisms become disrupted when patients experience ICANS. The study will test the hypothesis that cerebrospinal fluid catecholamines and multimodal magnetic resonance imaging are affected in this disorder.

To test this hypothesis, the study will measure cerebrospinal fluid catecholamines in ICANS patients and evaluate brain magnetic resonance imaging for these participants. This study may contribute to knowledge about brain biomarkers and imaging of ICANS, which will greatly aid in ICANS detection and prevention.

Conditions

Sponsors & Collaborators

  • Jinan Military General Hospital

    collaborator OTHER

  • Changhai Hospital

    collaborator OTHER

  • zhang shoulong

    lead OTHER

Principal Investigators

  • Shoulong Zhang · 980th Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-06
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05643092 on ClinicalTrials.gov